文献速递泌尿男性生殖肿瘤

帕博利珠单抗单药一线治疗晚期透明细胞肾细胞癌的II期研究

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2021-02-02

KEYNOTE-427研究A队列为开放标签、单臂II期试验,评估帕博利珠单抗200 mg每3周一次(最长24个月)一线治疗晚期透明细胞肾细胞癌的疗效与安全性。110例患者客观缓解率为36.4%,中位缓解持续时间18.9个月,中位无进展生存期7.1个月,中位总生存期未达到。

要点

  • 客观缓解率36.4%,含3.6%完全缓解,疾病控制率58.2%
  • 中位缓解持续时间18.9个月,64.1%的缓解者缓解≥12个月
  • 3-5级治疗相关不良事件发生率30.0%,以结肠炎和腹泻最常见

核心结论

  • 单药帕博利珠单抗在晚期透明细胞肾细胞癌一线治疗中显示出有前景的抗肿瘤活性,且在各IMDC危险分层中均观察到持久缓解。

研究设计与样本

  • 开放标签、单臂II期KEYNOTE-427研究A队列,纳入110例晚期透明细胞肾细胞癌初治患者。
  • 帕博利珠单抗200 mg每3周一次,最长24个月;主要终点为RECIST 1.1版客观缓解率。

主要发现

  • 客观缓解率36.4%,其中完全缓解4例(3.6%)、部分缓解36例(32.7%);疾病控制率58.2%(95% CI,48.4至67.5)。
  • 68.2%患者靶病灶缩小,其中30.9%缩小≥60%。
  • 中位缓解持续时间18.9(范围,2.3-37.6+)个月,64.1%的缓解者缓解≥12个月(Kaplan-Meier法)。
  • 中位无进展生存期7.1个月(95% CI,5.6至11.0);中位总生存期未达到,12个月和24个月总生存率分别为88.2%和70.8%。
  • 3-5级治疗相关不良事件发生率为30.0%,最常见为结肠炎和腹泻。

临床怎么用

  • 对于不适合或未接受其他一线治疗的晚期透明细胞肾细胞癌患者,帕博利珠单抗单药可作为备选方案之一,需关注免疫相关结肠炎和腹泻。

局限性

  • 本研究为单臂设计,未设对照组,客观缓解率等结果需在随机对照研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carcinoma (ccRCC; cohort A) and advanced non-ccRCC (cohort B). Results of cohort A are reported. METHODS: In this open-label, single-arm phase II study, patients with advanced ccRCC received pembrolizumab 200 mg every 3 weeks for ≤ 24 months. The primary end point was objective response rate by RECIST, version 1.1. RESULTS: In the total population (N = 110), median time from enrollment to data cutoff was 35.9 (range, 29.5-40.3) months. Objective response rate was 36.4% with four (3.6%) complete responses and 36 (32.7%) partial responses; disease control rate was 58.2% (95% CI, 48.4 to 67.5). Most patients (68.2%) had a decrease in target lesions, including 30.9% with a reduction ≥ 60%. Median duration of response was 18.9 (range, 2.3-37.6+) months; 64.1% of responders had a response ≥ 12 months (Kaplan-Meier). Median progression-free survival was 7.1 months (95% CI, 5.6 to 11.0). Median overall survival was not reached; 12-month and 24-month overall survival rates were 88.2% and 70.8%, respectively. Durable responses were observed across all International Metastatic RCC Database Consortium categories. Grade 3-5 treatment-related adverse events were reported in 30.0% of patients, of which colitis and diarrhea were most frequent. CONCLUSION: Single-agent pembrolizumab showed promising antitumor activity as a first-line treatment in patients with advanced ccRCC, with durable responses across International Metastatic RCC Database Consortium categories. Safety and tolerability profile of pembrolizumab monotherapy was comparable to what has been previously described in other tumor types.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McDermott DF, Lee JL, Bjarnason GA, et al. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021. PMID: 33529051. doi:10.1200/JCO.20.02363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。